Literature DB >> 19574960

Augmentation index relates to progression of aortic disease in adults with Marfan syndrome.

Kai Mortensen1, Muhammet A Aydin, Meike Rybczynski, Johannes Baulmann, Nazila Abdul Schahidi, Georgina Kean, Kristine Kühne, Alexander M J Bernhardt, Olaf Franzen, Thomas Mir, Christian Habermann, Dietmar Koschyk, Rodolfo Ventura, Stephan Willems, Peter N Robinson, Jürgen Berger, Hermann Reichenspurner, Thomas Meinertz, Yskert von Kodolitsch.   

Abstract

BACKGROUND: Noninvasive applanation tonometry (APT) is useful to assess aortic stiffness and pulse wave reflection. Moreover, APT can predict outcome in many conditions such as arterial hypertension. In this study, we test whether APT measurements relate to progression of aortic disease in Marfan syndrome (MFS).
METHODS: We performed APT in 50 consecutive, medically treated adults with MFS (19 men and 31 women aged 32 +/- 13 years), who had not undergone previous cardiovascular surgery. During 22 +/- 16 months of follow-up, 26 of these patients developed progression of aortic disease, which we defined as progression of aortic root diameters >or=5 mm/annum (18 individuals), aortic surgery >or=3 months after APT (seven individuals), or onset of acute aortic dissection any time after APT (one individual).
RESULTS: Univariate Cox regression analysis suggested an association of aortic disease progression with age (P = 0.001), total cholesterol levels (P = 0.04), aortic root diameter (P = 0.007), descending aorta diameter (P = 0.01), aortic root ratio (P = 0.02), and augmentation index (AIx@HR75; P < 0.006). Multivariate Cox regression analysis confirmed an independent impact on aortic disease progression exclusively for baseline aortic root diameters (hazard ratio = 1.347; 95% confidence interval (CI) 1.104-1.643; P = 0.003) and AIx@HR75 (hazard ratio = 1.246; 95% CI 1.029-1.508; P = 0.02). In addition, Kaplan-Meier survival curve analysis illustrated significantly lower rates of aortic root disease progression both with lower AIx@HR75 (P = 0.025) and with lower pulse wave velocity (PWV) values (P = 0.027).
CONCLUSIONS: We provide evidence that APT parameters relate to aortic disease progression in medically treated patients with MFS. We believe that APT has a potential to improve risk stratification in the clinical management of MFS patients.

Entities:  

Mesh:

Year:  2009        PMID: 19574960     DOI: 10.1038/ajh.2009.115

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  16 in total

1.  Pulse wave imaging for noninvasive and quantitative measurement of arterial stiffness in vivo.

Authors:  Jonathan Vappou; Jianwen Luo; Elisa E Konofagou
Journal:  Am J Hypertens       Date:  2010-01-21       Impact factor: 2.689

Review 2.  Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.

Authors:  Alain Li-Wan-Po; Bart Loeys; Peter Farndon; David Latham; Caroline Bradley
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

3.  Total serum transforming growth factor-β1 is elevated in the entire spectrum of genetic aortic syndromes.

Authors:  Mathias Hillebrand; Nathalie Millot; Sara Sheikhzadeh; Meike Rybczynski; Sabine Gerth; Tilo Kölbel; Britta Keyser; Kerstin Kutsche; Peter N Robinson; Jürgen Berger; Thomas S Mir; Tanja Zeller; Stefan Blankenberg; Yskert von Kodolitsch; Britta Goldmann
Journal:  Clin Cardiol       Date:  2014-08-11       Impact factor: 2.882

4.  Pulse wave analysis of the aortic pressure waveform in patients with vasovagal syncope.

Authors:  Simon Pecha; Samer Hakmi; Iris Wilke; Yalin Yildirim; Boris Hoffmann; Hermann Reichenspurner; Stephan Willems; Yskert von Kodolitsch; Ali Aydin
Journal:  Heart Vessels       Date:  2014-08-28       Impact factor: 2.037

5.  Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.

Authors:  Elif Seda Selamet Tierney; Jami C Levine; Lynn A Sleeper; Mary J Roman; Timothy J Bradley; Steven D Colan; Shan Chen; M Jay Campbell; Meryl S Cohen; Julie De Backer; Haleh Heydarian; Arvind Hoskoppal; Wyman W Lai; Aimee Liou; Edward Marcus; Arni Nutting; Aaron K Olson; David A Parra; Gail D Pearson; Mary Ella Pierpont; Beth F Printz; Reed E Pyeritz; William Ravekes; Angela M Sharkey; Shubhika Srivastava; Luciana Young; Ronald V Lacro
Journal:  Am J Cardiol       Date:  2018-02-13       Impact factor: 2.778

Review 6.  Potential predictors of severe cardiovascular involvement in Marfan syndrome: the emphasized role of genotype-phenotype correlations in improving risk stratification-a literature review.

Authors:  Zoltán Szabolcs; Kálmán Benke; Roland Stengl; Bence Ágg; Miklós Pólos; Gábor Mátyás; Gábor Szabó; Béla Merkely; Tamás Radovits
Journal:  Orphanet J Rare Dis       Date:  2021-05-31       Impact factor: 4.123

7.  D-dimer in Marfan syndrome: effect of obstructive sleep apnea induced blood pressure surges.

Authors:  Mudiaga Sowho; Hartmut Schneider; Jonathan Jun; Gretchen MacCarrick; Alan Schwartz; Luu Pham; Francis Sgambati; Joao Lima; Philip Smith; Vsevolod Polotsky; Enid Neptune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-11       Impact factor: 4.733

Review 8.  Marfan syndrome.

Authors:  Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz
Journal:  Nat Rev Dis Primers       Date:  2021-09-02       Impact factor: 65.038

Review 9.  Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome.

Authors:  Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson
Journal:  Appl Clin Genet       Date:  2015-06-16

10.  Augmentation index and aortic stiffness in bicuspid aortic valve patients with non-dilated proximal aortas.

Authors:  Patrick J Warner; Adeeb Al-Quthami; Erica L Brooks; Alyson Kelley-Hedgepeth; Eshan Patvardhan; Jeffrey T Kuvin; Kevin S Heffernan; Gordon S Huggins
Journal:  BMC Cardiovasc Disord       Date:  2013-03-15       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.